Gloria T Haskell1, Brian C Jensen2,3,4, Cecile Skrzynia5, Thelsa Pulikkotil3,6, Christian R Tilley5, Yurong Lu5, Daniel S Marchuk5, Leigh Ann Samsa4,7, Kirk C Wilhelmsen5,8, Ethan Lange5, Cam Patterson9, James P Evans5, Jonathan S Berg5. 1. Department of Genetics, University of North Carolina at Chapel Hill, NC, USA. Electronic correspondence: gloria.haskell@duke.edu. 2. Department of Pharmacology, University of North Carolina at Chapel Hill, NC, USA. 3. Division of Cardiology, Department of Medicine, University of North Carolina at Chapel Hill, NC, USA. 4. University of North Carolina McAllister Heart Institute, University of North Carolina at Chapel Hill, NC, USA. 5. Department of Genetics, University of North Carolina at Chapel Hill, NC, USA. 6. Kaiser Permanente, Atlanta, GA, USA. 7. Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, NC, USA. 8. Renaissance Computing Institute, Chapel Hill, NC, USA. 9. Departments of Medicine and Cardiology, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, USA.
Abstract
BACKGROUND: A genetic component to familial mitral valve prolapse (MVP) has been proposed for decades. Despite this, very few genes have been linked to MVP. Herein is described a four-generation pedigree with numerous individuals affected with severe MVP, some at strikingly young ages. METHODS: A detailed clinical evaluation performed on all affected family members demonstrated a spectrum of MVP morphologies and associated phenotypes. RESULTS: Linkage analysis failed to identify strong candidate loci, but revealed significant regions, which were investigated further using whole-exome sequencing of one of the severely affected family members. Whole-exome sequencing identified variants in this individual that fell within linkage analysis peak regions, but none was an obvious pathogenic candidate. Follow up segregation analysis of all exome-identified variants was performed to genotype other affected and unaffected individuals in the family, but no variants emerged as clear pathogenic candidates. Two notable variants of uncertain significance in candidate genes were identified: p.I1013S in PTPRJ at 11p11.2 and FLYWCH1 p.R540Q at 16p13.3. Neither gene has been previously linked to MVP in humans, although PTPRJ mutant mice display defects in endocardial cushions, which give rise to the cardiac valves. PTPRJ and FLYWCH1 expression was detected in adult human mitral valve cells, and in-silico analysis of these variants suggests they may be deleterious. However, neither variant segregated completely with all of the affected individuals in the family, particularly when 'affected' was broadly defined. CONCLUSIONS: While a contributory role for PTPRJ and FLYWCH1 in this family cannot be excluded, the study results underscored the difficulties involved in uncovering the genomic contribution to MVP, even in apparently Mendelian families.
BACKGROUND: A genetic component to familial mitral valve prolapse (MVP) has been proposed for decades. Despite this, very few genes have been linked to MVP. Herein is described a four-generation pedigree with numerous individuals affected with severe MVP, some at strikingly young ages. METHODS: A detailed clinical evaluation performed on all affected family members demonstrated a spectrum of MVP morphologies and associated phenotypes. RESULTS: Linkage analysis failed to identify strong candidate loci, but revealed significant regions, which were investigated further using whole-exome sequencing of one of the severely affected family members. Whole-exome sequencing identified variants in this individual that fell within linkage analysis peak regions, but none was an obvious pathogenic candidate. Follow up segregation analysis of all exome-identified variants was performed to genotype other affected and unaffected individuals in the family, but no variants emerged as clear pathogenic candidates. Two notable variants of uncertain significance in candidate genes were identified: p.I1013S in PTPRJ at 11p11.2 and FLYWCH1 p.R540Q at 16p13.3. Neither gene has been previously linked to MVP in humans, although PTPRJ mutant mice display defects in endocardial cushions, which give rise to the cardiac valves. PTPRJ and FLYWCH1 expression was detected in adult human mitral valve cells, and in-silico analysis of these variants suggests they may be deleterious. However, neither variant segregated completely with all of the affected individuals in the family, particularly when 'affected' was broadly defined. CONCLUSIONS: While a contributory role for PTPRJ and FLYWCH1 in this family cannot be excluded, the study results underscored the difficulties involved in uncovering the genomic contribution to MVP, even in apparently Mendelian families.
Authors: Lisa A Freed; James S Acierno; Daisy Dai; Maire Leyne; Jane E Marshall; Francesca Nesta; Robert A Levine; Susan A Slaugenhaupt Journal: Am J Hum Genet Date: 2003-04-21 Impact factor: 11.025
Authors: Francesca Nesta; Maire Leyne; Chaim Yosefy; Charles Simpson; Daisy Dai; Jane E Marshall; Judy Hung; Susan A Slaugenhaupt; Robert A Levine Journal: Circulation Date: 2005-09-19 Impact factor: 29.690
Authors: Takamune Takahashi; Keiko Takahashi; Patricia L St John; Paul A Fleming; Takuya Tomemori; Toshio Watanabe; Dale R Abrahamson; Christopher J Drake; Takuji Shirasawa; Thomas O Daniel Journal: Mol Cell Biol Date: 2003-03 Impact factor: 4.272
Authors: S Disse; E Abergel; A Berrebi; A M Houot; J Y Le Heuzey; B Diebold; L Guize; A Carpentier; P Corvol; X Jeunemaitre Journal: Am J Hum Genet Date: 1999-11 Impact factor: 11.025
Authors: Joseph F Nasuti; Paul J Zhang; Michael D Feldman; Terri Pasha; Jasvir S Khurana; Joseph H Gorman; Robert C Gorman; Jagat Narula; Navneet Narula Journal: Ann Thorac Surg Date: 2004-02 Impact factor: 4.330
Authors: Anneke J van der Kooi; Willem G de Voogt; Enrico Bertini; Luciano Merlini; F Beril Talim; Rabah Ben Yaou; Andoni Urtziberea; Marianne de Visser Journal: Arch Neurol Date: 2006-11